Information Provided By: 
Fly News Breaks for July 10, 2018
DXCM
Jul 10, 2018 | 07:56 EDT
BMO Capital analyst Joanne Wuensch raised her price target on DexCom to $112 as part of her broader Medical Technology: Mid-year View research note. The analyst cites "increasing confidence in the contribution from its product portfolio and pipeline as well as the health of the diabetes management market", adding that the company is positioned on the right side of a "secular trend towards better, automated management of diabetes". Wuensch also keeps her Outperform rating on DexCom.
News For DXCM From the Last 2 Days
DXCM
Apr 25, 2024 | 17:21 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here
DXCM
Apr 25, 2024 | 16:05 EDT
DXCM
Apr 25, 2024 | 16:04 EDT
DXCM
Apr 25, 2024 | 15:11 EDT
Pre-earnings options volume in DexCom is 11.4x normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 5.8%, or $8.05, after results are released. Median move over the past eight quarters is 5.4%.
DXCM
Apr 25, 2024 | 13:09 EDT
